Hyperion DeFi, Inc. Common Stock (HYPD)

Price$2.99

Value ScoreC

Growth ScoreB

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-41.63%

Price vs S&P 500 (4W)-16.93%

VGM Score50.03

Market Capitalization$45.32M

All Metrics

Book Value / Share (Quarterly)$5.12

P/TBV (Annual)7.06x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-84.00%

Cash Flow / Share (Quarterly)$-7.57

Price vs S&P 500 (YTD)-24.17%

Gross Margin (TTM)70.93%

Net Profit Margin (TTM)-2329.74%

EPS (TTM)$-3.92

10-Day Avg Trading Volume0.61M

EPS Excl Extra (TTM)$-3.92

Revenue Growth (5Y)-16.47%

EPS (Annual)$-9.06

Dividend / Share (Annual)$0.18

ROI (Annual)-92.75%

Gross Margin (Annual)62.72%

Net Profit Margin (5Y Avg)-162564.62%

Cash / Share (Quarterly)$0.65

Revenue Growth QoQ (YoY)1559.44%

ROA (Last FY)-87.54%

Revenue Growth TTM (YoY)1455.11%

EBITD / Share (TTM)$-1.46

ROE (5Y Avg)-153.50%

Operating Margin (TTM)-2335.54%

Cash Flow / Share (Annual)$-9.99

P/B Ratio0.77x

P/B Ratio (Quarterly)0.67x

Net Income / Employee (Annual)$-5,034,900

EV / Revenue (TTM)44.50x

Net Interest Coverage (TTM)-49.34x

ROA (TTM)-35.63%

EPS Incl Extra (Annual)$-9.06

Current Ratio (Annual)2.68x

Quick Ratio (Quarterly)1.76x

3-Month Avg Trading Volume0.46M

52-Week Price Return-4.78%

Revenue / Employee (TTM)$115,900

Tangible BV / Share (Quarterly)$3.72

P/S Ratio (Annual)55.71x

Asset Turnover (Annual)0.02x

52-Week High$17.18

Operating Margin (5Y Avg)-152377.62%

EPS Excl Extra (Annual)$-9.06

CapEx CAGR (5Y)207.90%

26-Week Price Return-33.70%

Quick Ratio (Annual)2.56x

13-Week Price Return-3.55%

Total Debt / Equity (Annual)0.19x

Current Ratio (Quarterly)1.97x

Enterprise Value$46.42M

Revenue / Share Growth (5Y)11.36%

Asset Turnover (TTM)0.02x

Revenue / Employee (Annual)$90,400

Pretax Margin (Annual)-5570.58%

Cash / Share (Annual)$0.74

3-Month Return Std Dev100.85%

Gross Margin (5Y Avg)-1307.55%

Net Income / Employee (TTM)$-2,699,900

ROE (Last FY)-110.36%

Net Interest Coverage (Annual)-18.46x

EPS Basic Excl Extra (Annual)$-9.06

Total Debt / Equity (Quarterly)0.14x

EPS Incl Extra (TTM)$-3.92

ROI (TTM)-37.53%

P/S Ratio (TTM)43.45x

Pretax Margin (5Y Avg)-162564.62%

Revenue / Share (Annual)$0.16

Tangible BV / Share (Annual)$0.48

Forward P/E2.35x

Price vs S&P 500 (52W)-29.14%

Year-to-Date Return-16.01%

5-Day Price Return-22.54%

EPS Normalized (Annual)$-9.06

ROA (5Y Avg)-334.23%

Net Profit Margin (Annual)-5570.58%

Month-to-Date Return-14.57%

EBITD / Share (Annual)$-8.87

Operating Margin (Annual)-5456.49%

LT Debt / Equity (Annual)0.19x

ROI (5Y Avg)-97.89%

LT Debt / Equity (Quarterly)0.12x

EPS Basic Excl Extra (TTM)$-3.92

P/TBV (Quarterly)0.93x

P/B Ratio (Annual)0.71x

Inventory Turnover (TTM)0.42x

Pretax Margin (TTM)-2329.74%

Book Value / Share (Annual)$4.73

Price vs S&P 500 (13W)-11.80%

Beta2.44x

Revenue / Share (TTM)$0.08

ROE (TTM)-42.80%

52-Week Low$2.11

vGradeC

gGradeB

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.26est. 0.74

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
HYPDHyperion DeFi, Inc. Common Stock	C	B	D	$2.99
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Eyenovia is a clinical-stage ophthalmic company developing novel treatments using its proprietary microarray print (MAP) platform and Optejet delivery system—a precision-targeted alternative to conventional eye droppers. The company's pipeline aims to improve drug safety, tolerability, patient compliance, and therapeutic efficacy across multiple eye disease indications. Eyenovia's smart ophthalmic therapies leverage novel formulations and drug combinations powered by its targeted delivery technology.